IBDEI0ET ; ; 03-MAY-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 03, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,37065,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37065,1,3,0)
;;=3^Burkitt Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,37065,1,4,0)
;;=4^C83.70
;;^UTILITY(U,$J,358.3,37065,2)
;;=^5001591
;;^UTILITY(U,$J,358.3,37066,0)
;;=D09.0^^107^1487^44
;;^UTILITY(U,$J,358.3,37066,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37066,1,3,0)
;;=3^Carcinoma in Situ of Bladder
;;^UTILITY(U,$J,358.3,37066,1,4,0)
;;=4^D09.0
;;^UTILITY(U,$J,358.3,37066,2)
;;=^267742
;;^UTILITY(U,$J,358.3,37067,0)
;;=D06.9^^107^1487^45
;;^UTILITY(U,$J,358.3,37067,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37067,1,3,0)
;;=3^Carcinoma in Situ of Cervix
;;^UTILITY(U,$J,358.3,37067,1,4,0)
;;=4^D06.9
;;^UTILITY(U,$J,358.3,37067,2)
;;=^5001941
;;^UTILITY(U,$J,358.3,37068,0)
;;=D06.0^^107^1487^47
;;^UTILITY(U,$J,358.3,37068,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37068,1,3,0)
;;=3^Carcinoma in Situ of Endocervix
;;^UTILITY(U,$J,358.3,37068,1,4,0)
;;=4^D06.0
;;^UTILITY(U,$J,358.3,37068,2)
;;=^5001938
;;^UTILITY(U,$J,358.3,37069,0)
;;=D06.1^^107^1487^48
;;^UTILITY(U,$J,358.3,37069,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37069,1,3,0)
;;=3^Carcinoma in Situ of Exocervix
;;^UTILITY(U,$J,358.3,37069,1,4,0)
;;=4^D06.1
;;^UTILITY(U,$J,358.3,37069,2)
;;=^5001939
;;^UTILITY(U,$J,358.3,37070,0)
;;=D06.7^^107^1487^46
;;^UTILITY(U,$J,358.3,37070,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37070,1,3,0)
;;=3^Carcinoma in Situ of Cervix,Other Parts
;;^UTILITY(U,$J,358.3,37070,1,4,0)
;;=4^D06.7
;;^UTILITY(U,$J,358.3,37070,2)
;;=^5001940
;;^UTILITY(U,$J,358.3,37071,0)
;;=D04.9^^107^1487^49
;;^UTILITY(U,$J,358.3,37071,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37071,1,3,0)
;;=3^Carcinoma in Situ of Skin
;;^UTILITY(U,$J,358.3,37071,1,4,0)
;;=4^D04.9
;;^UTILITY(U,$J,358.3,37071,2)
;;=^5001925
;;^UTILITY(U,$J,358.3,37072,0)
;;=C91.11^^107^1487^52
;;^UTILITY(U,$J,358.3,37072,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37072,1,3,0)
;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
;;^UTILITY(U,$J,358.3,37072,1,4,0)
;;=4^C91.11
;;^UTILITY(U,$J,358.3,37072,2)
;;=^5001766
;;^UTILITY(U,$J,358.3,37073,0)
;;=C91.10^^107^1487^53
;;^UTILITY(U,$J,358.3,37073,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37073,1,3,0)
;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
;;^UTILITY(U,$J,358.3,37073,1,4,0)
;;=4^C91.10
;;^UTILITY(U,$J,358.3,37073,2)
;;=^5001765
;;^UTILITY(U,$J,358.3,37074,0)
;;=C92.11^^107^1487^54
;;^UTILITY(U,$J,358.3,37074,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37074,1,3,0)
;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
;;^UTILITY(U,$J,358.3,37074,1,4,0)
;;=4^C92.11
;;^UTILITY(U,$J,358.3,37074,2)
;;=^5001793
;;^UTILITY(U,$J,358.3,37075,0)
;;=C92.10^^107^1487^55
;;^UTILITY(U,$J,358.3,37075,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37075,1,3,0)
;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
;;^UTILITY(U,$J,358.3,37075,1,4,0)
;;=4^C92.10
;;^UTILITY(U,$J,358.3,37075,2)
;;=^5001792
;;^UTILITY(U,$J,358.3,37076,0)
;;=D47.1^^107^1487^56
;;^UTILITY(U,$J,358.3,37076,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37076,1,3,0)
;;=3^Chronic Myeloproliferative Disease
;;^UTILITY(U,$J,358.3,37076,1,4,0)
;;=4^D47.1
;;^UTILITY(U,$J,358.3,37076,2)
;;=^5002256
;;^UTILITY(U,$J,358.3,37077,0)
;;=C82.69^^107^1487^57
;;^UTILITY(U,$J,358.3,37077,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37077,1,3,0)
;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,37077,1,4,0)
;;=4^C82.69
;;^UTILITY(U,$J,358.3,37077,2)
;;=^5001530
;;^UTILITY(U,$J,358.3,37078,0)
;;=C82.60^^107^1487^58
;;^UTILITY(U,$J,358.3,37078,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37078,1,3,0)
;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,37078,1,4,0)
;;=4^C82.60
;;^UTILITY(U,$J,358.3,37078,2)
;;=^5001521
;;^UTILITY(U,$J,358.3,37079,0)
;;=D56.2^^107^1487^59
;;^UTILITY(U,$J,358.3,37079,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37079,1,3,0)
;;=3^Delta-Beta Thalassemia
;;^UTILITY(U,$J,358.3,37079,1,4,0)
;;=4^D56.2
;;^UTILITY(U,$J,358.3,37079,2)
;;=^340496
;;^UTILITY(U,$J,358.3,37080,0)
;;=D75.9^^107^1487^60
;;^UTILITY(U,$J,358.3,37080,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37080,1,3,0)
;;=3^Disease of Blood/Blood-Forming Organs,Unspec
;;^UTILITY(U,$J,358.3,37080,1,4,0)
;;=4^D75.9
;;^UTILITY(U,$J,358.3,37080,2)
;;=^5002393
;;^UTILITY(U,$J,358.3,37081,0)
;;=D59.0^^107^1487^63
;;^UTILITY(U,$J,358.3,37081,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37081,1,3,0)
;;=3^Drug-Induced Autoimmune Hemolytic Anemia
;;^UTILITY(U,$J,358.3,37081,1,4,0)
;;=4^D59.0
;;^UTILITY(U,$J,358.3,37081,2)
;;=^5002323
;;^UTILITY(U,$J,358.3,37082,0)
;;=D59.2^^107^1487^64
;;^UTILITY(U,$J,358.3,37082,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37082,1,3,0)
;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
;;^UTILITY(U,$J,358.3,37082,1,4,0)
;;=4^D59.2
;;^UTILITY(U,$J,358.3,37082,2)
;;=^5002325
;;^UTILITY(U,$J,358.3,37083,0)
;;=R59.9^^107^1487^67
;;^UTILITY(U,$J,358.3,37083,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37083,1,3,0)
;;=3^Enlarged Lymph Nodes,Unspec
;;^UTILITY(U,$J,358.3,37083,1,4,0)
;;=4^R59.9
;;^UTILITY(U,$J,358.3,37083,2)
;;=^5019531
;;^UTILITY(U,$J,358.3,37084,0)
;;=D47.3^^107^1487^68
;;^UTILITY(U,$J,358.3,37084,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37084,1,3,0)
;;=3^Essential Thrombocythemia
;;^UTILITY(U,$J,358.3,37084,1,4,0)
;;=4^D47.3
;;^UTILITY(U,$J,358.3,37084,2)
;;=^5002258
;;^UTILITY(U,$J,358.3,37085,0)
;;=C82.09^^107^1487^69
;;^UTILITY(U,$J,358.3,37085,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37085,1,3,0)
;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,37085,1,4,0)
;;=4^C82.09
;;^UTILITY(U,$J,358.3,37085,2)
;;=^5001470
;;^UTILITY(U,$J,358.3,37086,0)
;;=C82.00^^107^1487^70
;;^UTILITY(U,$J,358.3,37086,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37086,1,3,0)
;;=3^Follicular Lymphoma Grade I,Unspec Site
;;^UTILITY(U,$J,358.3,37086,1,4,0)
;;=4^C82.00
;;^UTILITY(U,$J,358.3,37086,2)
;;=^5001461
;;^UTILITY(U,$J,358.3,37087,0)
;;=C82.19^^107^1487^71
;;^UTILITY(U,$J,358.3,37087,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37087,1,3,0)
;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,37087,1,4,0)
;;=4^C82.19
;;^UTILITY(U,$J,358.3,37087,2)
;;=^5001480
;;^UTILITY(U,$J,358.3,37088,0)
;;=C82.10^^107^1487^72
;;^UTILITY(U,$J,358.3,37088,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37088,1,3,0)
;;=3^Follicular Lymphoma Grade II,Unspec Site
;;^UTILITY(U,$J,358.3,37088,1,4,0)
;;=4^C82.10
;;^UTILITY(U,$J,358.3,37088,2)
;;=^5001471
;;^UTILITY(U,$J,358.3,37089,0)
;;=C82.29^^107^1487^73
;;^UTILITY(U,$J,358.3,37089,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37089,1,3,0)
;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,37089,1,4,0)
;;=4^C82.29
;;^UTILITY(U,$J,358.3,37089,2)
;;=^5001490
;;^UTILITY(U,$J,358.3,37090,0)
;;=C82.20^^107^1487^74
;;^UTILITY(U,$J,358.3,37090,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37090,1,3,0)
;;=3^Follicular Lymphoma Grade III,Unspec Site
;;^UTILITY(U,$J,358.3,37090,1,4,0)
;;=4^C82.20
;;^UTILITY(U,$J,358.3,37090,2)
;;=^5001481
;;^UTILITY(U,$J,358.3,37091,0)
;;=C82.39^^107^1487^75
;;^UTILITY(U,$J,358.3,37091,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37091,1,3,0)
;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,37091,1,4,0)
;;=4^C82.39
;;^UTILITY(U,$J,358.3,37091,2)
;;=^5001500
;;^UTILITY(U,$J,358.3,37092,0)
;;=C82.30^^107^1487^76
;;^UTILITY(U,$J,358.3,37092,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37092,1,3,0)
;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
;;^UTILITY(U,$J,358.3,37092,1,4,0)
;;=4^C82.30
;;^UTILITY(U,$J,358.3,37092,2)
;;=^5001491
;;^UTILITY(U,$J,358.3,37093,0)
;;=C82.49^^107^1487^77
;;^UTILITY(U,$J,358.3,37093,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37093,1,3,0)
;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,37093,1,4,0)
;;=4^C82.49
;;^UTILITY(U,$J,358.3,37093,2)
;;=^5001510
;;^UTILITY(U,$J,358.3,37094,0)
;;=C82.40^^107^1487^78
;;^UTILITY(U,$J,358.3,37094,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37094,1,3,0)
;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
;;^UTILITY(U,$J,358.3,37094,1,4,0)
;;=4^C82.40
;;^UTILITY(U,$J,358.3,37094,2)
;;=^5001501
;;^UTILITY(U,$J,358.3,37095,0)
;;=C82.99^^107^1487^79
;;^UTILITY(U,$J,358.3,37095,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37095,1,3,0)
;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,37095,1,4,0)
;;=4^C82.99
;;^UTILITY(U,$J,358.3,37095,2)
;;=^5001550
;;^UTILITY(U,$J,358.3,37096,0)
;;=C82.90^^107^1487^80
;;^UTILITY(U,$J,358.3,37096,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37096,1,3,0)
;;=3^Follicular Lymphoma Unspec,Unspec Site
;;^UTILITY(U,$J,358.3,37096,1,4,0)
;;=4^C82.90
;;^UTILITY(U,$J,358.3,37096,2)
;;=^5001541
;;^UTILITY(U,$J,358.3,37097,0)
;;=R59.1^^107^1487^65
;;^UTILITY(U,$J,358.3,37097,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37097,1,3,0)
;;=3^Enlarged Lymph Nodes,Generalized
;;^UTILITY(U,$J,358.3,37097,1,4,0)
;;=4^R59.1
;;^UTILITY(U,$J,358.3,37097,2)
;;=^5019530
;;^UTILITY(U,$J,358.3,37098,0)
;;=C91.40^^107^1487^84
;;^UTILITY(U,$J,358.3,37098,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37098,1,3,0)
;;=3^Hairy Cell Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,37098,1,4,0)
;;=4^C91.40
;;^UTILITY(U,$J,358.3,37098,2)
;;=^5001771
;;^UTILITY(U,$J,358.3,37099,0)
;;=C91.42^^107^1487^82
;;^UTILITY(U,$J,358.3,37099,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37099,1,3,0)
;;=3^Hairy Cell Leukemia,In Relapse
;;^UTILITY(U,$J,358.3,37099,1,4,0)
;;=4^C91.42
;;^UTILITY(U,$J,358.3,37099,2)
;;=^5001773
;;^UTILITY(U,$J,358.3,37100,0)
;;=C91.41^^107^1487^83
;;^UTILITY(U,$J,358.3,37100,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37100,1,3,0)
;;=3^Hairy Cell Leukemia,In Remission
;;^UTILITY(U,$J,358.3,37100,1,4,0)
;;=4^C91.41
;;^UTILITY(U,$J,358.3,37100,2)
;;=^5001772
;;^UTILITY(U,$J,358.3,37101,0)
;;=D57.01^^107^1487^85
;;^UTILITY(U,$J,358.3,37101,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37101,1,3,0)
;;=3^Hb-SS Disease w/ Acute Chest Syndrome
;;^UTILITY(U,$J,358.3,37101,1,4,0)
;;=4^D57.01
;;^UTILITY(U,$J,358.3,37101,2)
;;=^5002307
;;^UTILITY(U,$J,358.3,37102,0)
;;=D57.00^^107^1487^86
;;^UTILITY(U,$J,358.3,37102,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37102,1,3,0)
;;=3^Hb-SS Disease w/ Crisis,Unspec
;;^UTILITY(U,$J,358.3,37102,1,4,0)
;;=4^D57.00
;;^UTILITY(U,$J,358.3,37102,2)
;;=^5002306
;;^UTILITY(U,$J,358.3,37103,0)
;;=D57.02^^107^1487^87
;;^UTILITY(U,$J,358.3,37103,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37103,1,3,0)
;;=3^Hb-SS Disease w/ Splenic Sequestration
;;^UTILITY(U,$J,358.3,37103,1,4,0)
;;=4^D57.02
;;^UTILITY(U,$J,358.3,37103,2)
;;=^5002308
;;^UTILITY(U,$J,358.3,37104,0)
;;=D68.32^^107^1487^89
;;^UTILITY(U,$J,358.3,37104,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37104,1,3,0)
;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
;;^UTILITY(U,$J,358.3,37104,1,4,0)
;;=4^D68.32
;;^UTILITY(U,$J,358.3,37104,2)
;;=^5002357
;;^UTILITY(U,$J,358.3,37105,0)
;;=C22.2^^107^1487^90
;;^UTILITY(U,$J,358.3,37105,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37105,1,3,0)
;;=3^Hepatoblastoma
;;^UTILITY(U,$J,358.3,37105,1,4,0)
;;=4^C22.2
;;^UTILITY(U,$J,358.3,37105,2)
;;=^5000935
;;^UTILITY(U,$J,358.3,37106,0)
;;=D58.9^^107^1487^92
;;^UTILITY(U,$J,358.3,37106,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37106,1,3,0)
;;=3^Hereditary Hemolytic Anemia,Unspec
;;^UTILITY(U,$J,358.3,37106,1,4,0)
;;=4^D58.9
;;^UTILITY(U,$J,358.3,37106,2)
;;=^5002322
;;^UTILITY(U,$J,358.3,37107,0)
;;=C81.99^^107^1487^93
;;^UTILITY(U,$J,358.3,37107,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37107,1,3,0)
;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,37107,1,4,0)
;;=4^C81.99
;;^UTILITY(U,$J,358.3,37107,2)
;;=^5001460
;;^UTILITY(U,$J,358.3,37108,0)
;;=C81.90^^107^1487^94
;;^UTILITY(U,$J,358.3,37108,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37108,1,3,0)
;;=3^Hodgkin Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,37108,1,4,0)
;;=4^C81.90
;;^UTILITY(U,$J,358.3,37108,2)
;;=^5001451
;;^UTILITY(U,$J,358.3,37109,0)
;;=D89.2^^107^1487^95
;;^UTILITY(U,$J,358.3,37109,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37109,1,3,0)
;;=3^Hypergammaglobulenemia,Unspec
;;^UTILITY(U,$J,358.3,37109,1,4,0)
;;=4^D89.2
;;^UTILITY(U,$J,358.3,37109,2)
;;=^5002455
;;^UTILITY(U,$J,358.3,37110,0)
;;=D05.12^^107^1487^98
;;^UTILITY(U,$J,358.3,37110,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37110,1,3,0)
;;=3^Intraductal Carcinoma in Situ,Left Breast
;;^UTILITY(U,$J,358.3,37110,1,4,0)
;;=4^D05.12
;;^UTILITY(U,$J,358.3,37110,2)
;;=^5001931
;;^UTILITY(U,$J,358.3,37111,0)
;;=D05.11^^107^1487^99
;;^UTILITY(U,$J,358.3,37111,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37111,1,3,0)
;;=3^Intraductal Carcinoma in Situ,Right Breast
;;^UTILITY(U,$J,358.3,37111,1,4,0)
;;=4^D05.11
;;^UTILITY(U,$J,358.3,37111,2)
;;=^5001930
;;^UTILITY(U,$J,358.3,37112,0)
;;=D05.10^^107^1487^100
;;^UTILITY(U,$J,358.3,37112,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37112,1,3,0)
;;=3^Intraductal Carcinoma in Situ,Unspec Breast
;;^UTILITY(U,$J,358.3,37112,1,4,0)
;;=4^D05.10
;;^UTILITY(U,$J,358.3,37112,2)
;;=^5001929
;;^UTILITY(U,$J,358.3,37113,0)
;;=D50.0^^107^1487^101
;;^UTILITY(U,$J,358.3,37113,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37113,1,3,0)
;;=3^Iron Deficiency Anemia Secondary to Blood Loss
;;^UTILITY(U,$J,358.3,37113,1,4,0)
;;=4^D50.0
;;^UTILITY(U,$J,358.3,37113,2)
;;=^267971
;;^UTILITY(U,$J,358.3,37114,0)
;;=D50.9^^107^1487^102
;;^UTILITY(U,$J,358.3,37114,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37114,1,3,0)
;;=3^Iron Deficiency Anemia,Unspec
;;^UTILITY(U,$J,358.3,37114,1,4,0)
;;=4^D50.9
;;^UTILITY(U,$J,358.3,37114,2)
;;=^5002283
;;^UTILITY(U,$J,358.3,37115,0)
;;=C46.9^^107^1487^103
;;^UTILITY(U,$J,358.3,37115,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37115,1,3,0)
;;=3^Kaposi's Sarcoma,Unspec
;;^UTILITY(U,$J,358.3,37115,1,4,0)
;;=4^C46.9
;;^UTILITY(U,$J,358.3,37115,2)
;;=^5001108
;;^UTILITY(U,$J,358.3,37116,0)
;;=C22.0^^107^1487^104
;;^UTILITY(U,$J,358.3,37116,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37116,1,3,0)
;;=3^Liver Cell Carcinoma
;;^UTILITY(U,$J,358.3,37116,1,4,0)
;;=4^C22.0
;;^UTILITY(U,$J,358.3,37116,2)
;;=^5000933
;;^UTILITY(U,$J,358.3,37117,0)
;;=D05.02^^107^1487^105
;;^UTILITY(U,$J,358.3,37117,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37117,1,3,0)
;;=3^Lobular Carcinoma in Situ,Left Breast
;;^UTILITY(U,$J,358.3,37117,1,4,0)
;;=4^D05.02
;;^UTILITY(U,$J,358.3,37117,2)
;;=^5001928
;;^UTILITY(U,$J,358.3,37118,0)
;;=D05.01^^107^1487^106
;;^UTILITY(U,$J,358.3,37118,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37118,1,3,0)
;;=3^Lobular Carcinoma in Situ,Right Breast
;;^UTILITY(U,$J,358.3,37118,1,4,0)
;;=4^D05.01
;;^UTILITY(U,$J,358.3,37118,2)
;;=^5001927
;;^UTILITY(U,$J,358.3,37119,0)
;;=D05.00^^107^1487^107
;;^UTILITY(U,$J,358.3,37119,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37119,1,3,0)
;;=3^Lobular Carcinoma in Situ,Unspec Breast
;;^UTILITY(U,$J,358.3,37119,1,4,0)
;;=4^D05.00
;;^UTILITY(U,$J,358.3,37119,2)
;;=^5001926
;;^UTILITY(U,$J,358.3,37120,0)
;;=R59.0^^107^1487^66
;;^UTILITY(U,$J,358.3,37120,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37120,1,3,0)
;;=3^Enlarged Lymph Nodes,Localized
;;^UTILITY(U,$J,358.3,37120,1,4,0)
;;=4^R59.0
;;^UTILITY(U,$J,358.3,37120,2)
;;=^5019529
;;^UTILITY(U,$J,358.3,37121,0)
;;=C83.59^^107^1487^108
;;^UTILITY(U,$J,358.3,37121,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37121,1,3,0)
;;=3^Lymphoblastic Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,37121,1,4,0)
;;=4^C83.59
;;^UTILITY(U,$J,358.3,37121,2)
;;=^5001590
;;^UTILITY(U,$J,358.3,37122,0)
;;=C83.50^^107^1487^109
;;^UTILITY(U,$J,358.3,37122,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37122,1,3,0)
;;=3^Lymphoblastic Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,37122,1,4,0)
;;=4^C83.50
;;^UTILITY(U,$J,358.3,37122,2)
;;=^5001581
;;^UTILITY(U,$J,358.3,37123,0)
;;=C43.9^^107^1487^112
;;^UTILITY(U,$J,358.3,37123,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37123,1,3,0)
;;=3^Malig Melanoma of Skin,Unspec Site
;;^UTILITY(U,$J,358.3,37123,1,4,0)
;;=4^C43.9
;;^UTILITY(U,$J,358.3,37123,2)
;;=^5001015
;;^UTILITY(U,$J,358.3,37124,0)
;;=C31.9^^107^1487^113
;;^UTILITY(U,$J,358.3,37124,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37124,1,3,0)
;;=3^Malig Neop Accessory Sinus,Unspec
;;^UTILITY(U,$J,358.3,37124,1,4,0)
;;=4^C31.9
;;^UTILITY(U,$J,358.3,37124,2)
;;=^5000953
;;^UTILITY(U,$J,358.3,37125,0)
;;=C24.1^^107^1487^115
;;^UTILITY(U,$J,358.3,37125,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37125,1,3,0)
;;=3^Malig Neop Ampulla of Vater
;;^UTILITY(U,$J,358.3,37125,1,4,0)
;;=4^C24.1
;;^UTILITY(U,$J,358.3,37125,2)
;;=^267100
;;^UTILITY(U,$J,358.3,37126,0)
;;=C21.0^^107^1487^116
;;^UTILITY(U,$J,358.3,37126,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37126,1,3,0)
;;=3^Malig Neop Anus,Unspec
;;^UTILITY(U,$J,358.3,37126,1,4,0)
;;=4^C21.0
;;^UTILITY(U,$J,358.3,37126,2)
;;=^5000930
;;^UTILITY(U,$J,358.3,37127,0)
;;=C67.9^^107^1487^119
;;^UTILITY(U,$J,358.3,37127,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37127,1,3,0)
;;=3^Malig Neop Bladder,Unspec
;;^UTILITY(U,$J,358.3,37127,1,4,0)
;;=4^C67.9
;;^UTILITY(U,$J,358.3,37127,2)
;;=^5001263
;;^UTILITY(U,$J,358.3,37128,0)
;;=C71.9^^107^1487^123
;;^UTILITY(U,$J,358.3,37128,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37128,1,3,0)
;;=3^Malig Neop Brain,Unspec
;;^UTILITY(U,$J,358.3,37128,1,4,0)
;;=4^C71.9
;;^UTILITY(U,$J,358.3,37128,2)
;;=^5001297
;;^UTILITY(U,$J,358.3,37129,0)
;;=C18.9^^107^1487^125
;;^UTILITY(U,$J,358.3,37129,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37129,1,3,0)
;;=3^Malig Neop Colon,Unspec
;;^UTILITY(U,$J,358.3,37129,1,4,0)
;;=4^C18.9
;;^UTILITY(U,$J,358.3,37129,2)
;;=^5000929
;;^UTILITY(U,$J,358.3,37130,0)
;;=C49.9^^107^1487^126
;;^UTILITY(U,$J,358.3,37130,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37130,1,3,0)
;;=3^Malig Neop Connective/Soft Tissue,Unspec
;;^UTILITY(U,$J,358.3,37130,1,4,0)
;;=4^C49.9
;;^UTILITY(U,$J,358.3,37130,2)
;;=^5001136
;;^UTILITY(U,$J,358.3,37131,0)
;;=C62.12^^107^1487^127
;;^UTILITY(U,$J,358.3,37131,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,37131,1,3,0)
;;=3^Malig Neop Descended Left Testis
;;^UTILITY(U,$J,358.3,37131,1,4,0)
;;=4^C62.12
;;^UTILITY(U,$J,358.3,37131,2)
;;=^5001235
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0ET 19782 printed Apr 09, 2024@21:05:45 Page 2
IBDEI0ET ; ; 03-MAY-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 03, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,37065,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,37065,1,3,0)
+4 ;;=3^Burkitt Lymphoma,Unspec Site
+5 ;;^UTILITY(U,$J,358.3,37065,1,4,0)
+6 ;;=4^C83.70
+7 ;;^UTILITY(U,$J,358.3,37065,2)
+8 ;;=^5001591
+9 ;;^UTILITY(U,$J,358.3,37066,0)
+10 ;;=D09.0^^107^1487^44
+11 ;;^UTILITY(U,$J,358.3,37066,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,37066,1,3,0)
+14 ;;=3^Carcinoma in Situ of Bladder
+15 ;;^UTILITY(U,$J,358.3,37066,1,4,0)
+16 ;;=4^D09.0
+17 ;;^UTILITY(U,$J,358.3,37066,2)
+18 ;;=^267742
+19 ;;^UTILITY(U,$J,358.3,37067,0)
+20 ;;=D06.9^^107^1487^45
+21 ;;^UTILITY(U,$J,358.3,37067,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,37067,1,3,0)
+24 ;;=3^Carcinoma in Situ of Cervix
+25 ;;^UTILITY(U,$J,358.3,37067,1,4,0)
+26 ;;=4^D06.9
+27 ;;^UTILITY(U,$J,358.3,37067,2)
+28 ;;=^5001941
+29 ;;^UTILITY(U,$J,358.3,37068,0)
+30 ;;=D06.0^^107^1487^47
+31 ;;^UTILITY(U,$J,358.3,37068,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,37068,1,3,0)
+34 ;;=3^Carcinoma in Situ of Endocervix
+35 ;;^UTILITY(U,$J,358.3,37068,1,4,0)
+36 ;;=4^D06.0
+37 ;;^UTILITY(U,$J,358.3,37068,2)
+38 ;;=^5001938
+39 ;;^UTILITY(U,$J,358.3,37069,0)
+40 ;;=D06.1^^107^1487^48
+41 ;;^UTILITY(U,$J,358.3,37069,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,37069,1,3,0)
+44 ;;=3^Carcinoma in Situ of Exocervix
+45 ;;^UTILITY(U,$J,358.3,37069,1,4,0)
+46 ;;=4^D06.1
+47 ;;^UTILITY(U,$J,358.3,37069,2)
+48 ;;=^5001939
+49 ;;^UTILITY(U,$J,358.3,37070,0)
+50 ;;=D06.7^^107^1487^46
+51 ;;^UTILITY(U,$J,358.3,37070,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,37070,1,3,0)
+54 ;;=3^Carcinoma in Situ of Cervix,Other Parts
+55 ;;^UTILITY(U,$J,358.3,37070,1,4,0)
+56 ;;=4^D06.7
+57 ;;^UTILITY(U,$J,358.3,37070,2)
+58 ;;=^5001940
+59 ;;^UTILITY(U,$J,358.3,37071,0)
+60 ;;=D04.9^^107^1487^49
+61 ;;^UTILITY(U,$J,358.3,37071,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,37071,1,3,0)
+64 ;;=3^Carcinoma in Situ of Skin
+65 ;;^UTILITY(U,$J,358.3,37071,1,4,0)
+66 ;;=4^D04.9
+67 ;;^UTILITY(U,$J,358.3,37071,2)
+68 ;;=^5001925
+69 ;;^UTILITY(U,$J,358.3,37072,0)
+70 ;;=C91.11^^107^1487^52
+71 ;;^UTILITY(U,$J,358.3,37072,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,37072,1,3,0)
+74 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
+75 ;;^UTILITY(U,$J,358.3,37072,1,4,0)
+76 ;;=4^C91.11
+77 ;;^UTILITY(U,$J,358.3,37072,2)
+78 ;;=^5001766
+79 ;;^UTILITY(U,$J,358.3,37073,0)
+80 ;;=C91.10^^107^1487^53
+81 ;;^UTILITY(U,$J,358.3,37073,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,37073,1,3,0)
+84 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
+85 ;;^UTILITY(U,$J,358.3,37073,1,4,0)
+86 ;;=4^C91.10
+87 ;;^UTILITY(U,$J,358.3,37073,2)
+88 ;;=^5001765
+89 ;;^UTILITY(U,$J,358.3,37074,0)
+90 ;;=C92.11^^107^1487^54
+91 ;;^UTILITY(U,$J,358.3,37074,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,37074,1,3,0)
+94 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
+95 ;;^UTILITY(U,$J,358.3,37074,1,4,0)
+96 ;;=4^C92.11
+97 ;;^UTILITY(U,$J,358.3,37074,2)
+98 ;;=^5001793
+99 ;;^UTILITY(U,$J,358.3,37075,0)
+100 ;;=C92.10^^107^1487^55
+101 ;;^UTILITY(U,$J,358.3,37075,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,37075,1,3,0)
+104 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
+105 ;;^UTILITY(U,$J,358.3,37075,1,4,0)
+106 ;;=4^C92.10
+107 ;;^UTILITY(U,$J,358.3,37075,2)
+108 ;;=^5001792
+109 ;;^UTILITY(U,$J,358.3,37076,0)
+110 ;;=D47.1^^107^1487^56
+111 ;;^UTILITY(U,$J,358.3,37076,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,37076,1,3,0)
+114 ;;=3^Chronic Myeloproliferative Disease
+115 ;;^UTILITY(U,$J,358.3,37076,1,4,0)
+116 ;;=4^D47.1
+117 ;;^UTILITY(U,$J,358.3,37076,2)
+118 ;;=^5002256
+119 ;;^UTILITY(U,$J,358.3,37077,0)
+120 ;;=C82.69^^107^1487^57
+121 ;;^UTILITY(U,$J,358.3,37077,1,0)
+122 ;;=^358.31IA^4^2
+123 ;;^UTILITY(U,$J,358.3,37077,1,3,0)
+124 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
+125 ;;^UTILITY(U,$J,358.3,37077,1,4,0)
+126 ;;=4^C82.69
+127 ;;^UTILITY(U,$J,358.3,37077,2)
+128 ;;=^5001530
+129 ;;^UTILITY(U,$J,358.3,37078,0)
+130 ;;=C82.60^^107^1487^58
+131 ;;^UTILITY(U,$J,358.3,37078,1,0)
+132 ;;=^358.31IA^4^2
+133 ;;^UTILITY(U,$J,358.3,37078,1,3,0)
+134 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
+135 ;;^UTILITY(U,$J,358.3,37078,1,4,0)
+136 ;;=4^C82.60
+137 ;;^UTILITY(U,$J,358.3,37078,2)
+138 ;;=^5001521
+139 ;;^UTILITY(U,$J,358.3,37079,0)
+140 ;;=D56.2^^107^1487^59
+141 ;;^UTILITY(U,$J,358.3,37079,1,0)
+142 ;;=^358.31IA^4^2
+143 ;;^UTILITY(U,$J,358.3,37079,1,3,0)
+144 ;;=3^Delta-Beta Thalassemia
+145 ;;^UTILITY(U,$J,358.3,37079,1,4,0)
+146 ;;=4^D56.2
+147 ;;^UTILITY(U,$J,358.3,37079,2)
+148 ;;=^340496
+149 ;;^UTILITY(U,$J,358.3,37080,0)
+150 ;;=D75.9^^107^1487^60
+151 ;;^UTILITY(U,$J,358.3,37080,1,0)
+152 ;;=^358.31IA^4^2
+153 ;;^UTILITY(U,$J,358.3,37080,1,3,0)
+154 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
+155 ;;^UTILITY(U,$J,358.3,37080,1,4,0)
+156 ;;=4^D75.9
+157 ;;^UTILITY(U,$J,358.3,37080,2)
+158 ;;=^5002393
+159 ;;^UTILITY(U,$J,358.3,37081,0)
+160 ;;=D59.0^^107^1487^63
+161 ;;^UTILITY(U,$J,358.3,37081,1,0)
+162 ;;=^358.31IA^4^2
+163 ;;^UTILITY(U,$J,358.3,37081,1,3,0)
+164 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
+165 ;;^UTILITY(U,$J,358.3,37081,1,4,0)
+166 ;;=4^D59.0
+167 ;;^UTILITY(U,$J,358.3,37081,2)
+168 ;;=^5002323
+169 ;;^UTILITY(U,$J,358.3,37082,0)
+170 ;;=D59.2^^107^1487^64
+171 ;;^UTILITY(U,$J,358.3,37082,1,0)
+172 ;;=^358.31IA^4^2
+173 ;;^UTILITY(U,$J,358.3,37082,1,3,0)
+174 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
+175 ;;^UTILITY(U,$J,358.3,37082,1,4,0)
+176 ;;=4^D59.2
+177 ;;^UTILITY(U,$J,358.3,37082,2)
+178 ;;=^5002325
+179 ;;^UTILITY(U,$J,358.3,37083,0)
+180 ;;=R59.9^^107^1487^67
+181 ;;^UTILITY(U,$J,358.3,37083,1,0)
+182 ;;=^358.31IA^4^2
+183 ;;^UTILITY(U,$J,358.3,37083,1,3,0)
+184 ;;=3^Enlarged Lymph Nodes,Unspec
+185 ;;^UTILITY(U,$J,358.3,37083,1,4,0)
+186 ;;=4^R59.9
+187 ;;^UTILITY(U,$J,358.3,37083,2)
+188 ;;=^5019531
+189 ;;^UTILITY(U,$J,358.3,37084,0)
+190 ;;=D47.3^^107^1487^68
+191 ;;^UTILITY(U,$J,358.3,37084,1,0)
+192 ;;=^358.31IA^4^2
+193 ;;^UTILITY(U,$J,358.3,37084,1,3,0)
+194 ;;=3^Essential Thrombocythemia
+195 ;;^UTILITY(U,$J,358.3,37084,1,4,0)
+196 ;;=4^D47.3
+197 ;;^UTILITY(U,$J,358.3,37084,2)
+198 ;;=^5002258
+199 ;;^UTILITY(U,$J,358.3,37085,0)
+200 ;;=C82.09^^107^1487^69
+201 ;;^UTILITY(U,$J,358.3,37085,1,0)
+202 ;;=^358.31IA^4^2
+203 ;;^UTILITY(U,$J,358.3,37085,1,3,0)
+204 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
+205 ;;^UTILITY(U,$J,358.3,37085,1,4,0)
+206 ;;=4^C82.09
+207 ;;^UTILITY(U,$J,358.3,37085,2)
+208 ;;=^5001470
+209 ;;^UTILITY(U,$J,358.3,37086,0)
+210 ;;=C82.00^^107^1487^70
+211 ;;^UTILITY(U,$J,358.3,37086,1,0)
+212 ;;=^358.31IA^4^2
+213 ;;^UTILITY(U,$J,358.3,37086,1,3,0)
+214 ;;=3^Follicular Lymphoma Grade I,Unspec Site
+215 ;;^UTILITY(U,$J,358.3,37086,1,4,0)
+216 ;;=4^C82.00
+217 ;;^UTILITY(U,$J,358.3,37086,2)
+218 ;;=^5001461
+219 ;;^UTILITY(U,$J,358.3,37087,0)
+220 ;;=C82.19^^107^1487^71
+221 ;;^UTILITY(U,$J,358.3,37087,1,0)
+222 ;;=^358.31IA^4^2
+223 ;;^UTILITY(U,$J,358.3,37087,1,3,0)
+224 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
+225 ;;^UTILITY(U,$J,358.3,37087,1,4,0)
+226 ;;=4^C82.19
+227 ;;^UTILITY(U,$J,358.3,37087,2)
+228 ;;=^5001480
+229 ;;^UTILITY(U,$J,358.3,37088,0)
+230 ;;=C82.10^^107^1487^72
+231 ;;^UTILITY(U,$J,358.3,37088,1,0)
+232 ;;=^358.31IA^4^2
+233 ;;^UTILITY(U,$J,358.3,37088,1,3,0)
+234 ;;=3^Follicular Lymphoma Grade II,Unspec Site
+235 ;;^UTILITY(U,$J,358.3,37088,1,4,0)
+236 ;;=4^C82.10
+237 ;;^UTILITY(U,$J,358.3,37088,2)
+238 ;;=^5001471
+239 ;;^UTILITY(U,$J,358.3,37089,0)
+240 ;;=C82.29^^107^1487^73
+241 ;;^UTILITY(U,$J,358.3,37089,1,0)
+242 ;;=^358.31IA^4^2
+243 ;;^UTILITY(U,$J,358.3,37089,1,3,0)
+244 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
+245 ;;^UTILITY(U,$J,358.3,37089,1,4,0)
+246 ;;=4^C82.29
+247 ;;^UTILITY(U,$J,358.3,37089,2)
+248 ;;=^5001490
+249 ;;^UTILITY(U,$J,358.3,37090,0)
+250 ;;=C82.20^^107^1487^74
+251 ;;^UTILITY(U,$J,358.3,37090,1,0)
+252 ;;=^358.31IA^4^2
+253 ;;^UTILITY(U,$J,358.3,37090,1,3,0)
+254 ;;=3^Follicular Lymphoma Grade III,Unspec Site
+255 ;;^UTILITY(U,$J,358.3,37090,1,4,0)
+256 ;;=4^C82.20
+257 ;;^UTILITY(U,$J,358.3,37090,2)
+258 ;;=^5001481
+259 ;;^UTILITY(U,$J,358.3,37091,0)
+260 ;;=C82.39^^107^1487^75
+261 ;;^UTILITY(U,$J,358.3,37091,1,0)
+262 ;;=^358.31IA^4^2
+263 ;;^UTILITY(U,$J,358.3,37091,1,3,0)
+264 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
+265 ;;^UTILITY(U,$J,358.3,37091,1,4,0)
+266 ;;=4^C82.39
+267 ;;^UTILITY(U,$J,358.3,37091,2)
+268 ;;=^5001500
+269 ;;^UTILITY(U,$J,358.3,37092,0)
+270 ;;=C82.30^^107^1487^76
+271 ;;^UTILITY(U,$J,358.3,37092,1,0)
+272 ;;=^358.31IA^4^2
+273 ;;^UTILITY(U,$J,358.3,37092,1,3,0)
+274 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
+275 ;;^UTILITY(U,$J,358.3,37092,1,4,0)
+276 ;;=4^C82.30
+277 ;;^UTILITY(U,$J,358.3,37092,2)
+278 ;;=^5001491
+279 ;;^UTILITY(U,$J,358.3,37093,0)
+280 ;;=C82.49^^107^1487^77
+281 ;;^UTILITY(U,$J,358.3,37093,1,0)
+282 ;;=^358.31IA^4^2
+283 ;;^UTILITY(U,$J,358.3,37093,1,3,0)
+284 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
+285 ;;^UTILITY(U,$J,358.3,37093,1,4,0)
+286 ;;=4^C82.49
+287 ;;^UTILITY(U,$J,358.3,37093,2)
+288 ;;=^5001510
+289 ;;^UTILITY(U,$J,358.3,37094,0)
+290 ;;=C82.40^^107^1487^78
+291 ;;^UTILITY(U,$J,358.3,37094,1,0)
+292 ;;=^358.31IA^4^2
+293 ;;^UTILITY(U,$J,358.3,37094,1,3,0)
+294 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
+295 ;;^UTILITY(U,$J,358.3,37094,1,4,0)
+296 ;;=4^C82.40
+297 ;;^UTILITY(U,$J,358.3,37094,2)
+298 ;;=^5001501
+299 ;;^UTILITY(U,$J,358.3,37095,0)
+300 ;;=C82.99^^107^1487^79
+301 ;;^UTILITY(U,$J,358.3,37095,1,0)
+302 ;;=^358.31IA^4^2
+303 ;;^UTILITY(U,$J,358.3,37095,1,3,0)
+304 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
+305 ;;^UTILITY(U,$J,358.3,37095,1,4,0)
+306 ;;=4^C82.99
+307 ;;^UTILITY(U,$J,358.3,37095,2)
+308 ;;=^5001550
+309 ;;^UTILITY(U,$J,358.3,37096,0)
+310 ;;=C82.90^^107^1487^80
+311 ;;^UTILITY(U,$J,358.3,37096,1,0)
+312 ;;=^358.31IA^4^2
+313 ;;^UTILITY(U,$J,358.3,37096,1,3,0)
+314 ;;=3^Follicular Lymphoma Unspec,Unspec Site
+315 ;;^UTILITY(U,$J,358.3,37096,1,4,0)
+316 ;;=4^C82.90
+317 ;;^UTILITY(U,$J,358.3,37096,2)
+318 ;;=^5001541
+319 ;;^UTILITY(U,$J,358.3,37097,0)
+320 ;;=R59.1^^107^1487^65
+321 ;;^UTILITY(U,$J,358.3,37097,1,0)
+322 ;;=^358.31IA^4^2
+323 ;;^UTILITY(U,$J,358.3,37097,1,3,0)
+324 ;;=3^Enlarged Lymph Nodes,Generalized
+325 ;;^UTILITY(U,$J,358.3,37097,1,4,0)
+326 ;;=4^R59.1
+327 ;;^UTILITY(U,$J,358.3,37097,2)
+328 ;;=^5019530
+329 ;;^UTILITY(U,$J,358.3,37098,0)
+330 ;;=C91.40^^107^1487^84
+331 ;;^UTILITY(U,$J,358.3,37098,1,0)
+332 ;;=^358.31IA^4^2
+333 ;;^UTILITY(U,$J,358.3,37098,1,3,0)
+334 ;;=3^Hairy Cell Leukemia,Not in Remission
+335 ;;^UTILITY(U,$J,358.3,37098,1,4,0)
+336 ;;=4^C91.40
+337 ;;^UTILITY(U,$J,358.3,37098,2)
+338 ;;=^5001771
+339 ;;^UTILITY(U,$J,358.3,37099,0)
+340 ;;=C91.42^^107^1487^82
+341 ;;^UTILITY(U,$J,358.3,37099,1,0)
+342 ;;=^358.31IA^4^2
+343 ;;^UTILITY(U,$J,358.3,37099,1,3,0)
+344 ;;=3^Hairy Cell Leukemia,In Relapse
+345 ;;^UTILITY(U,$J,358.3,37099,1,4,0)
+346 ;;=4^C91.42
+347 ;;^UTILITY(U,$J,358.3,37099,2)
+348 ;;=^5001773
+349 ;;^UTILITY(U,$J,358.3,37100,0)
+350 ;;=C91.41^^107^1487^83
+351 ;;^UTILITY(U,$J,358.3,37100,1,0)
+352 ;;=^358.31IA^4^2
+353 ;;^UTILITY(U,$J,358.3,37100,1,3,0)
+354 ;;=3^Hairy Cell Leukemia,In Remission
+355 ;;^UTILITY(U,$J,358.3,37100,1,4,0)
+356 ;;=4^C91.41
+357 ;;^UTILITY(U,$J,358.3,37100,2)
+358 ;;=^5001772
+359 ;;^UTILITY(U,$J,358.3,37101,0)
+360 ;;=D57.01^^107^1487^85
+361 ;;^UTILITY(U,$J,358.3,37101,1,0)
+362 ;;=^358.31IA^4^2
+363 ;;^UTILITY(U,$J,358.3,37101,1,3,0)
+364 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
+365 ;;^UTILITY(U,$J,358.3,37101,1,4,0)
+366 ;;=4^D57.01
+367 ;;^UTILITY(U,$J,358.3,37101,2)
+368 ;;=^5002307
+369 ;;^UTILITY(U,$J,358.3,37102,0)
+370 ;;=D57.00^^107^1487^86
+371 ;;^UTILITY(U,$J,358.3,37102,1,0)
+372 ;;=^358.31IA^4^2
+373 ;;^UTILITY(U,$J,358.3,37102,1,3,0)
+374 ;;=3^Hb-SS Disease w/ Crisis,Unspec
+375 ;;^UTILITY(U,$J,358.3,37102,1,4,0)
+376 ;;=4^D57.00
+377 ;;^UTILITY(U,$J,358.3,37102,2)
+378 ;;=^5002306
+379 ;;^UTILITY(U,$J,358.3,37103,0)
+380 ;;=D57.02^^107^1487^87
+381 ;;^UTILITY(U,$J,358.3,37103,1,0)
+382 ;;=^358.31IA^4^2
+383 ;;^UTILITY(U,$J,358.3,37103,1,3,0)
+384 ;;=3^Hb-SS Disease w/ Splenic Sequestration
+385 ;;^UTILITY(U,$J,358.3,37103,1,4,0)
+386 ;;=4^D57.02
+387 ;;^UTILITY(U,$J,358.3,37103,2)
+388 ;;=^5002308
+389 ;;^UTILITY(U,$J,358.3,37104,0)
+390 ;;=D68.32^^107^1487^89
+391 ;;^UTILITY(U,$J,358.3,37104,1,0)
+392 ;;=^358.31IA^4^2
+393 ;;^UTILITY(U,$J,358.3,37104,1,3,0)
+394 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
+395 ;;^UTILITY(U,$J,358.3,37104,1,4,0)
+396 ;;=4^D68.32
+397 ;;^UTILITY(U,$J,358.3,37104,2)
+398 ;;=^5002357
+399 ;;^UTILITY(U,$J,358.3,37105,0)
+400 ;;=C22.2^^107^1487^90
+401 ;;^UTILITY(U,$J,358.3,37105,1,0)
+402 ;;=^358.31IA^4^2
+403 ;;^UTILITY(U,$J,358.3,37105,1,3,0)
+404 ;;=3^Hepatoblastoma
+405 ;;^UTILITY(U,$J,358.3,37105,1,4,0)
+406 ;;=4^C22.2
+407 ;;^UTILITY(U,$J,358.3,37105,2)
+408 ;;=^5000935
+409 ;;^UTILITY(U,$J,358.3,37106,0)
+410 ;;=D58.9^^107^1487^92
+411 ;;^UTILITY(U,$J,358.3,37106,1,0)
+412 ;;=^358.31IA^4^2
+413 ;;^UTILITY(U,$J,358.3,37106,1,3,0)
+414 ;;=3^Hereditary Hemolytic Anemia,Unspec
+415 ;;^UTILITY(U,$J,358.3,37106,1,4,0)
+416 ;;=4^D58.9
+417 ;;^UTILITY(U,$J,358.3,37106,2)
+418 ;;=^5002322
+419 ;;^UTILITY(U,$J,358.3,37107,0)
+420 ;;=C81.99^^107^1487^93
+421 ;;^UTILITY(U,$J,358.3,37107,1,0)
+422 ;;=^358.31IA^4^2
+423 ;;^UTILITY(U,$J,358.3,37107,1,3,0)
+424 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
+425 ;;^UTILITY(U,$J,358.3,37107,1,4,0)
+426 ;;=4^C81.99
+427 ;;^UTILITY(U,$J,358.3,37107,2)
+428 ;;=^5001460
+429 ;;^UTILITY(U,$J,358.3,37108,0)
+430 ;;=C81.90^^107^1487^94
+431 ;;^UTILITY(U,$J,358.3,37108,1,0)
+432 ;;=^358.31IA^4^2
+433 ;;^UTILITY(U,$J,358.3,37108,1,3,0)
+434 ;;=3^Hodgkin Lymphoma,Unspec Site
+435 ;;^UTILITY(U,$J,358.3,37108,1,4,0)
+436 ;;=4^C81.90
+437 ;;^UTILITY(U,$J,358.3,37108,2)
+438 ;;=^5001451
+439 ;;^UTILITY(U,$J,358.3,37109,0)
+440 ;;=D89.2^^107^1487^95
+441 ;;^UTILITY(U,$J,358.3,37109,1,0)
+442 ;;=^358.31IA^4^2
+443 ;;^UTILITY(U,$J,358.3,37109,1,3,0)
+444 ;;=3^Hypergammaglobulenemia,Unspec
+445 ;;^UTILITY(U,$J,358.3,37109,1,4,0)
+446 ;;=4^D89.2
+447 ;;^UTILITY(U,$J,358.3,37109,2)
+448 ;;=^5002455
+449 ;;^UTILITY(U,$J,358.3,37110,0)
+450 ;;=D05.12^^107^1487^98
+451 ;;^UTILITY(U,$J,358.3,37110,1,0)
+452 ;;=^358.31IA^4^2
+453 ;;^UTILITY(U,$J,358.3,37110,1,3,0)
+454 ;;=3^Intraductal Carcinoma in Situ,Left Breast
+455 ;;^UTILITY(U,$J,358.3,37110,1,4,0)
+456 ;;=4^D05.12
+457 ;;^UTILITY(U,$J,358.3,37110,2)
+458 ;;=^5001931
+459 ;;^UTILITY(U,$J,358.3,37111,0)
+460 ;;=D05.11^^107^1487^99
+461 ;;^UTILITY(U,$J,358.3,37111,1,0)
+462 ;;=^358.31IA^4^2
+463 ;;^UTILITY(U,$J,358.3,37111,1,3,0)
+464 ;;=3^Intraductal Carcinoma in Situ,Right Breast
+465 ;;^UTILITY(U,$J,358.3,37111,1,4,0)
+466 ;;=4^D05.11
+467 ;;^UTILITY(U,$J,358.3,37111,2)
+468 ;;=^5001930
+469 ;;^UTILITY(U,$J,358.3,37112,0)
+470 ;;=D05.10^^107^1487^100
+471 ;;^UTILITY(U,$J,358.3,37112,1,0)
+472 ;;=^358.31IA^4^2
+473 ;;^UTILITY(U,$J,358.3,37112,1,3,0)
+474 ;;=3^Intraductal Carcinoma in Situ,Unspec Breast
+475 ;;^UTILITY(U,$J,358.3,37112,1,4,0)
+476 ;;=4^D05.10
+477 ;;^UTILITY(U,$J,358.3,37112,2)
+478 ;;=^5001929
+479 ;;^UTILITY(U,$J,358.3,37113,0)
+480 ;;=D50.0^^107^1487^101
+481 ;;^UTILITY(U,$J,358.3,37113,1,0)
+482 ;;=^358.31IA^4^2
+483 ;;^UTILITY(U,$J,358.3,37113,1,3,0)
+484 ;;=3^Iron Deficiency Anemia Secondary to Blood Loss
+485 ;;^UTILITY(U,$J,358.3,37113,1,4,0)
+486 ;;=4^D50.0
+487 ;;^UTILITY(U,$J,358.3,37113,2)
+488 ;;=^267971
+489 ;;^UTILITY(U,$J,358.3,37114,0)
+490 ;;=D50.9^^107^1487^102
+491 ;;^UTILITY(U,$J,358.3,37114,1,0)
+492 ;;=^358.31IA^4^2
+493 ;;^UTILITY(U,$J,358.3,37114,1,3,0)
+494 ;;=3^Iron Deficiency Anemia,Unspec
+495 ;;^UTILITY(U,$J,358.3,37114,1,4,0)
+496 ;;=4^D50.9
+497 ;;^UTILITY(U,$J,358.3,37114,2)
+498 ;;=^5002283
+499 ;;^UTILITY(U,$J,358.3,37115,0)
+500 ;;=C46.9^^107^1487^103
+501 ;;^UTILITY(U,$J,358.3,37115,1,0)
+502 ;;=^358.31IA^4^2
+503 ;;^UTILITY(U,$J,358.3,37115,1,3,0)
+504 ;;=3^Kaposi's Sarcoma,Unspec
+505 ;;^UTILITY(U,$J,358.3,37115,1,4,0)
+506 ;;=4^C46.9
+507 ;;^UTILITY(U,$J,358.3,37115,2)
+508 ;;=^5001108
+509 ;;^UTILITY(U,$J,358.3,37116,0)
+510 ;;=C22.0^^107^1487^104
+511 ;;^UTILITY(U,$J,358.3,37116,1,0)
+512 ;;=^358.31IA^4^2
+513 ;;^UTILITY(U,$J,358.3,37116,1,3,0)
+514 ;;=3^Liver Cell Carcinoma
+515 ;;^UTILITY(U,$J,358.3,37116,1,4,0)
+516 ;;=4^C22.0
+517 ;;^UTILITY(U,$J,358.3,37116,2)
+518 ;;=^5000933
+519 ;;^UTILITY(U,$J,358.3,37117,0)
+520 ;;=D05.02^^107^1487^105
+521 ;;^UTILITY(U,$J,358.3,37117,1,0)
+522 ;;=^358.31IA^4^2
+523 ;;^UTILITY(U,$J,358.3,37117,1,3,0)
+524 ;;=3^Lobular Carcinoma in Situ,Left Breast
+525 ;;^UTILITY(U,$J,358.3,37117,1,4,0)
+526 ;;=4^D05.02
+527 ;;^UTILITY(U,$J,358.3,37117,2)
+528 ;;=^5001928
+529 ;;^UTILITY(U,$J,358.3,37118,0)
+530 ;;=D05.01^^107^1487^106
+531 ;;^UTILITY(U,$J,358.3,37118,1,0)
+532 ;;=^358.31IA^4^2
+533 ;;^UTILITY(U,$J,358.3,37118,1,3,0)
+534 ;;=3^Lobular Carcinoma in Situ,Right Breast
+535 ;;^UTILITY(U,$J,358.3,37118,1,4,0)
+536 ;;=4^D05.01
+537 ;;^UTILITY(U,$J,358.3,37118,2)
+538 ;;=^5001927
+539 ;;^UTILITY(U,$J,358.3,37119,0)
+540 ;;=D05.00^^107^1487^107
+541 ;;^UTILITY(U,$J,358.3,37119,1,0)
+542 ;;=^358.31IA^4^2
+543 ;;^UTILITY(U,$J,358.3,37119,1,3,0)
+544 ;;=3^Lobular Carcinoma in Situ,Unspec Breast
+545 ;;^UTILITY(U,$J,358.3,37119,1,4,0)
+546 ;;=4^D05.00
+547 ;;^UTILITY(U,$J,358.3,37119,2)
+548 ;;=^5001926
+549 ;;^UTILITY(U,$J,358.3,37120,0)
+550 ;;=R59.0^^107^1487^66
+551 ;;^UTILITY(U,$J,358.3,37120,1,0)
+552 ;;=^358.31IA^4^2
+553 ;;^UTILITY(U,$J,358.3,37120,1,3,0)
+554 ;;=3^Enlarged Lymph Nodes,Localized
+555 ;;^UTILITY(U,$J,358.3,37120,1,4,0)
+556 ;;=4^R59.0
+557 ;;^UTILITY(U,$J,358.3,37120,2)
+558 ;;=^5019529
+559 ;;^UTILITY(U,$J,358.3,37121,0)
+560 ;;=C83.59^^107^1487^108
+561 ;;^UTILITY(U,$J,358.3,37121,1,0)
+562 ;;=^358.31IA^4^2
+563 ;;^UTILITY(U,$J,358.3,37121,1,3,0)
+564 ;;=3^Lymphoblastic Lymphoma,Extranodal/Solid Organ Sites
+565 ;;^UTILITY(U,$J,358.3,37121,1,4,0)
+566 ;;=4^C83.59
+567 ;;^UTILITY(U,$J,358.3,37121,2)
+568 ;;=^5001590
+569 ;;^UTILITY(U,$J,358.3,37122,0)
+570 ;;=C83.50^^107^1487^109
+571 ;;^UTILITY(U,$J,358.3,37122,1,0)
+572 ;;=^358.31IA^4^2
+573 ;;^UTILITY(U,$J,358.3,37122,1,3,0)
+574 ;;=3^Lymphoblastic Lymphoma,Unspec Site
+575 ;;^UTILITY(U,$J,358.3,37122,1,4,0)
+576 ;;=4^C83.50
+577 ;;^UTILITY(U,$J,358.3,37122,2)
+578 ;;=^5001581
+579 ;;^UTILITY(U,$J,358.3,37123,0)
+580 ;;=C43.9^^107^1487^112
+581 ;;^UTILITY(U,$J,358.3,37123,1,0)
+582 ;;=^358.31IA^4^2
+583 ;;^UTILITY(U,$J,358.3,37123,1,3,0)
+584 ;;=3^Malig Melanoma of Skin,Unspec Site
+585 ;;^UTILITY(U,$J,358.3,37123,1,4,0)
+586 ;;=4^C43.9
+587 ;;^UTILITY(U,$J,358.3,37123,2)
+588 ;;=^5001015
+589 ;;^UTILITY(U,$J,358.3,37124,0)
+590 ;;=C31.9^^107^1487^113
+591 ;;^UTILITY(U,$J,358.3,37124,1,0)
+592 ;;=^358.31IA^4^2
+593 ;;^UTILITY(U,$J,358.3,37124,1,3,0)
+594 ;;=3^Malig Neop Accessory Sinus,Unspec
+595 ;;^UTILITY(U,$J,358.3,37124,1,4,0)
+596 ;;=4^C31.9
+597 ;;^UTILITY(U,$J,358.3,37124,2)
+598 ;;=^5000953
+599 ;;^UTILITY(U,$J,358.3,37125,0)
+600 ;;=C24.1^^107^1487^115
+601 ;;^UTILITY(U,$J,358.3,37125,1,0)
+602 ;;=^358.31IA^4^2
+603 ;;^UTILITY(U,$J,358.3,37125,1,3,0)
+604 ;;=3^Malig Neop Ampulla of Vater
+605 ;;^UTILITY(U,$J,358.3,37125,1,4,0)
+606 ;;=4^C24.1
+607 ;;^UTILITY(U,$J,358.3,37125,2)
+608 ;;=^267100
+609 ;;^UTILITY(U,$J,358.3,37126,0)
+610 ;;=C21.0^^107^1487^116
+611 ;;^UTILITY(U,$J,358.3,37126,1,0)
+612 ;;=^358.31IA^4^2
+613 ;;^UTILITY(U,$J,358.3,37126,1,3,0)
+614 ;;=3^Malig Neop Anus,Unspec
+615 ;;^UTILITY(U,$J,358.3,37126,1,4,0)
+616 ;;=4^C21.0
+617 ;;^UTILITY(U,$J,358.3,37126,2)
+618 ;;=^5000930
+619 ;;^UTILITY(U,$J,358.3,37127,0)
+620 ;;=C67.9^^107^1487^119
+621 ;;^UTILITY(U,$J,358.3,37127,1,0)
+622 ;;=^358.31IA^4^2
+623 ;;^UTILITY(U,$J,358.3,37127,1,3,0)
+624 ;;=3^Malig Neop Bladder,Unspec
+625 ;;^UTILITY(U,$J,358.3,37127,1,4,0)
+626 ;;=4^C67.9
+627 ;;^UTILITY(U,$J,358.3,37127,2)
+628 ;;=^5001263
+629 ;;^UTILITY(U,$J,358.3,37128,0)
+630 ;;=C71.9^^107^1487^123
+631 ;;^UTILITY(U,$J,358.3,37128,1,0)
+632 ;;=^358.31IA^4^2
+633 ;;^UTILITY(U,$J,358.3,37128,1,3,0)
+634 ;;=3^Malig Neop Brain,Unspec
+635 ;;^UTILITY(U,$J,358.3,37128,1,4,0)
+636 ;;=4^C71.9
+637 ;;^UTILITY(U,$J,358.3,37128,2)
+638 ;;=^5001297
+639 ;;^UTILITY(U,$J,358.3,37129,0)
+640 ;;=C18.9^^107^1487^125
+641 ;;^UTILITY(U,$J,358.3,37129,1,0)
+642 ;;=^358.31IA^4^2
+643 ;;^UTILITY(U,$J,358.3,37129,1,3,0)
+644 ;;=3^Malig Neop Colon,Unspec
+645 ;;^UTILITY(U,$J,358.3,37129,1,4,0)
+646 ;;=4^C18.9
+647 ;;^UTILITY(U,$J,358.3,37129,2)
+648 ;;=^5000929
+649 ;;^UTILITY(U,$J,358.3,37130,0)
+650 ;;=C49.9^^107^1487^126
+651 ;;^UTILITY(U,$J,358.3,37130,1,0)
+652 ;;=^358.31IA^4^2
+653 ;;^UTILITY(U,$J,358.3,37130,1,3,0)
+654 ;;=3^Malig Neop Connective/Soft Tissue,Unspec
+655 ;;^UTILITY(U,$J,358.3,37130,1,4,0)
+656 ;;=4^C49.9
+657 ;;^UTILITY(U,$J,358.3,37130,2)
+658 ;;=^5001136
+659 ;;^UTILITY(U,$J,358.3,37131,0)
+660 ;;=C62.12^^107^1487^127
+661 ;;^UTILITY(U,$J,358.3,37131,1,0)
+662 ;;=^358.31IA^4^2
+663 ;;^UTILITY(U,$J,358.3,37131,1,3,0)
+664 ;;=3^Malig Neop Descended Left Testis
+665 ;;^UTILITY(U,$J,358.3,37131,1,4,0)
+666 ;;=4^C62.12
+667 ;;^UTILITY(U,$J,358.3,37131,2)
+668 ;;=^5001235
